Cargando…
Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder that still lacks an efficient therapy. The barriers between the central nervous system (CNS) and the blood represent a major limiting factor to the development of drugs for CNS diseases, including ALS. Alterations of the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319288/ https://www.ncbi.nlm.nih.gov/pubmed/35887567 http://dx.doi.org/10.3390/jpm12071071 |
_version_ | 1784755513067569152 |
---|---|
author | Alarcan, Hugo Al Ojaimi, Yara Lanznaster, Debora Escoffre, Jean-Michel Corcia, Philippe Vourc’h, Patrick Andres, Christian R. Veyrat-Durebex, Charlotte Blasco, Hélène |
author_facet | Alarcan, Hugo Al Ojaimi, Yara Lanznaster, Debora Escoffre, Jean-Michel Corcia, Philippe Vourc’h, Patrick Andres, Christian R. Veyrat-Durebex, Charlotte Blasco, Hélène |
author_sort | Alarcan, Hugo |
collection | PubMed |
description | Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder that still lacks an efficient therapy. The barriers between the central nervous system (CNS) and the blood represent a major limiting factor to the development of drugs for CNS diseases, including ALS. Alterations of the blood–brain barrier (BBB) or blood–spinal cord barrier (BSCB) have been reported in this disease but still require further investigations. Interestingly, these alterations might be involved in the complex etiology and pathogenesis of ALS. Moreover, they can have potential consequences on the diffusion of candidate drugs across the brain. The development of techniques to bypass these barriers is continuously evolving and might open the door for personalized medical approaches. Therefore, identifying robust and non-invasive markers of BBB and BSCB alterations can help distinguish different subgroups of patients, such as those in whom barrier disruption can negatively affect the delivery of drugs to their CNS targets. The restoration of CNS barriers using innovative therapies could consequently present the advantage of both alleviating the disease progression and optimizing the safety and efficiency of ALS-specific therapies. |
format | Online Article Text |
id | pubmed-9319288 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93192882022-07-27 Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS? Alarcan, Hugo Al Ojaimi, Yara Lanznaster, Debora Escoffre, Jean-Michel Corcia, Philippe Vourc’h, Patrick Andres, Christian R. Veyrat-Durebex, Charlotte Blasco, Hélène J Pers Med Review Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder that still lacks an efficient therapy. The barriers between the central nervous system (CNS) and the blood represent a major limiting factor to the development of drugs for CNS diseases, including ALS. Alterations of the blood–brain barrier (BBB) or blood–spinal cord barrier (BSCB) have been reported in this disease but still require further investigations. Interestingly, these alterations might be involved in the complex etiology and pathogenesis of ALS. Moreover, they can have potential consequences on the diffusion of candidate drugs across the brain. The development of techniques to bypass these barriers is continuously evolving and might open the door for personalized medical approaches. Therefore, identifying robust and non-invasive markers of BBB and BSCB alterations can help distinguish different subgroups of patients, such as those in whom barrier disruption can negatively affect the delivery of drugs to their CNS targets. The restoration of CNS barriers using innovative therapies could consequently present the advantage of both alleviating the disease progression and optimizing the safety and efficiency of ALS-specific therapies. MDPI 2022-06-29 /pmc/articles/PMC9319288/ /pubmed/35887567 http://dx.doi.org/10.3390/jpm12071071 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Alarcan, Hugo Al Ojaimi, Yara Lanznaster, Debora Escoffre, Jean-Michel Corcia, Philippe Vourc’h, Patrick Andres, Christian R. Veyrat-Durebex, Charlotte Blasco, Hélène Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS? |
title | Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS? |
title_full | Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS? |
title_fullStr | Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS? |
title_full_unstemmed | Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS? |
title_short | Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS? |
title_sort | taking advantages of blood–brain or spinal cord barrier alterations or restoring them to optimize therapy in als? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319288/ https://www.ncbi.nlm.nih.gov/pubmed/35887567 http://dx.doi.org/10.3390/jpm12071071 |
work_keys_str_mv | AT alarcanhugo takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT alojaimiyara takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT lanznasterdebora takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT escoffrejeanmichel takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT corciaphilippe takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT vourchpatrick takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT andreschristianr takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT veyratdurebexcharlotte takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals AT blascohelene takingadvantagesofbloodbrainorspinalcordbarrieralterationsorrestoringthemtooptimizetherapyinals |